Background Drug-resistance mutations (DRAM) are frequently selected in patients with virological failure defined as viral load (pVL) above 500 copies/ml (c/mL), but few resistance data are available at low-level viremia (LLV). Our objective was to determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving antiretroviral therapy (ART). Methods Retrospective analysis of patients presenting a LLV episode defined as pVL between 40 and 500 c/mL on at least 3 occasions during a 6-month period or longer while on the same ART. Resistance genotypic testing was performed at the onset and at the end of LLV period. Emerging DRAM was defined during LLV if never detected on baseline genotype or before. Results 48 patients including 4 naive and 44 pretreated (median 9 years) presented a LLV episode with a median duration of 11 months. Current ART included 2NRTI (94%), ritonavir-boosted PI (94%), NNRTI (23%), and/or raltegravir (19%). Median pVL during LLV was 134 c/mL. Successful resistance testing at both onset and end of the LLV episode were obtained for 37 patients (77%), among who 11 (30%) acquired at least 1 DRAM during the LLV period: for NRTI in 6, for NNRTI in 1, for PI in 4, and for raltegravir in 2. During the LLV period, number of drugs with genotypic resistance increased from a median of 4.5 to 6 drugs. Duration and pVL level of LLV episode, duration of previous ART, current and nadir CD4 count, number of baseline DRAM and GSS were not identified as predictive factors of resistance acquisition during LLV, probably due to limited number of patients. Conclusion Persistent LLV episodes below 500 c/ml while receiving ART is associated with emerging DRAM for all drug classes and a decreasing in further therapeutic options, suggesting to earlier consider resistance monitoring and ART optimization in this setting.
References
[1]
Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, et al. (2007) Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 46: 12–18.
[2]
Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, et al. (2007) Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Aids 21: 721–732.
[3]
Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, et al. (2004) Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. Aids 18: 1503–1511.
[4]
Recommandations , du groupe d'experts sous la direction du Pr Delfraissy (2004) Prise en charge médicale des personnes infectées par le VIH; Ministère de la Santé et des Sports.
[5]
Recommandations , du groupe d'experts sous la direction du Pr Yeni (2006) Prise en charge médicale des personnes infectées par le VIH. Ministère de la Santé et des Sports.
[6]
Recommandations , du groupe d'experts sous la direction du Pr Yeni (2010) Prise en charge médicale des personnes infectées par le VIH: Ministère de la Santé et des Sports.
[7]
The European AIDS Clinical Society (2011) Guidelines for treatment of HIV infected adults in Europe. Version 6.0. October 2011; 1–60. Available: http://www.europeanaidsclinicalsociety.o？rg/images/stories/EACS-Pdf/eacsguideline？s-6.pdf.
[8]
Bansi L, Sabin C, Delpech V, Hill T, Fisher M, et al. (2010) Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med 11: 432–438.
[9]
Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, et al. (2009) Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. Aids 23: 717–724.
[10]
Delaugerre C, Ghosn J, Lacombe J-M, Pialoux G, Cuzin L, et al. (2011) Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention Rome.
[11]
Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, et al. (2004) Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Aids 18: 981–989.
[12]
Pilcher CD, Miller WC, Beatty ZA, Eron JJ (1999) Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. Aids 13: 1337–1342.
[13]
Hull M, Loufty M, Zhang W, Shen A, Druyts E, et al. (2010) Persistent low-level viremia is associated with increased risk of virologic failure and mortality. San Francisco.
[14]
Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin AG, et al. (2010) Prevalence of HIV-1 drug resistance in treated patients with viral load>50 copies/ml in 2009: a French nationwide study; International HIV Drug Resistance Workshop Dubrovnik.
[15]
Department of Health and Human Services (2011) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 10, 2011; 1–166. Available: http://www.aidsinfo.nih.gov/ContentFiles？/AdultandAdolescentGL.pdf.
[16]
Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, et al. (2004) The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. Aids 18: 1147–1158.
[17]
von Wyl V, Yerly S, Boni J, Shah C, Cellerai C, et al. (2011) Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clin Infect Dis.
[18]
Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, et al. (2004) Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 189: 51–60.
[19]
King MS, Brun SC, Kempf DJ (2005) Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 191: 2046–2052.
[20]
Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, et al. (2011) Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 204: 1191–1201.
[21]
Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG (2006) Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 7: 437–441.
[22]
Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, et al. (2011) Antiretroviral Drug Resistance in HIV-1-Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy. J Infect Dis 204: 515–520.
[23]
Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, et al. (2011) Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. Aids 25: 665–669.
[24]
Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, et al. (2010) Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scand J Infect Dis 42: 527–532.
[25]
Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, et al. (2010) Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. Aids 24: 2651–2656.
